Skip to main content

Table 1 Causes of anti-HIV first-line therapy discontinuation in the study population (n=1,096)

From: Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study

Type Tot Strata n % Over strata % Over total
Adverse events (toxicity/allergy) 302 (1 death) Gastrointestinal 86 28.5% 7.8%
   Hypersensitivity 28 9.3% 2.6%
   Central nervous system 18 6.0% 1.6%
   Hepatic 14 4.6% 1.3%
   Metabolic (glucose or lipid metabolism, lipodystrophy) 34 11.3% 3.1%
   Renal 13 4.3% 1.2%
   Hematologic 40 13.2% 3.6%
   Other 69 22.8% 6.3%
Other causes 618 Simplification 252 40.8% 23.0%
   Patient’s choice 93 15.0% 8.5%
   Failure 86 13.9% 7.8%
   Regimen intensification 59 9.5% 5.4%
   Genotype-guided switch 20 3.2% 1.8%
   Low adherence 19 3.1% 1.7%
   End of pregnancy 16 2.6% 1.5%
   Structured interruption 13 2.1% 1.2%
   Enrolment in a new prospective study 13 2.1% 1.2%
   Pregnancy 12 1.9% 1.1%
   Other 35 5.7% 3.2%
Non-discontinued 176 (6 deaths) N/A 176 100% 16.1%